JMH
ADMS

J.M. Hartwell’s Adamas Pharmaceuticals ADMS Stock Holding History

J.M. Hartwell’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-13,000
Closed -$92K – 85
2019
Q1 		$92K Sell
13,000
-1,500
-10% -$13.5K 0.02% 76
2018
Q4 		$124K Sell
14,500
-5,500
-28% -$71.5K 0.03% 76
2018
Q3 		$400K Buy
20,000
+3,500
+21% +$82.2K 0.07% 70
2018
Q2 		$426K Sell
16,500
-4,000
-20% -$111K 0.08% 71
2018
Q1 		$490K Buy
20,500
+4,000
+24% +$126K 0.09% 64
2017
Q4 		$559K Buy
16,500
+6,500
+65% +$181K 0.11% 57
2017
Q3 		$212K Buy
+10,000
New +$183K 0.04% 81

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
DAM
Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

J.M. Hartwell's ADMS Position: Q2 2019 in Review

J.M. Hartwell sold out of Adamas Pharmaceuticals (ADMS) in Q2 2019, closing a stake of 13,000 shares — an estimated $92K sold.

J.M. Hartwell first reported a position in ADMS in Q3 2017 and held it in 7 quarters. The position peaked at $559K in Q4 2017. 78 funds tracked by Wall St. Rank hold ADMS as of Q2 2019.

  • J.M. Hartwell reported no remaining Adamas Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • J.M. Hartwell sold 13,000 Adamas Pharmaceuticals shares in Q2 2019, an estimated $92K.
  • J.M. Hartwell first reported a position in Adamas Pharmaceuticals in Q3 2017 and held it in 7 quarters.
  • J.M. Hartwell's Adamas Pharmaceuticals position peaked at $559K in Q4 2017.
  • 78 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2019.

Based on J.M. Hartwell's 13F filing for Q2 2019, filed 31 Jul 2019.